Feed PBLA
PB

Panbela Therapeutics, Inc.

PBLA · OTC

$0.01 +0.00% (+$0.00)
1M +1,109,900.00%
Market Cap $53.9K
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Moderate
4/9
Valuation
-
N/A
P/FCF N/A
P/E N/A
P/FFO N/A
Growth
-
N/A
FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A
Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor
Asset turnover 0.00x
ROIC 10,520.50%
ROA 214.06%
Debt
57 /100
Moderate
Int. coverage 81.28x
Current ratio 0.25x
Debt/Assets N/A
Stability
1 /100
Unstable
Profitable years 0
Beta 1.88x
EPS volatility 233.84%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about PBLA
Online

About the company

Panbela Therapeutics, Inc. (PBLA) is a biotechnology company specializing in the development of novel therapeutic approaches for combating cancer. The company focuses on researching and developing drugs that target specific molecular mechanisms in tumor cells to suppress tumor growth and improve overall patient survival. Panbela Therapeutics concentrates on innovative immunotherapies that can enhance the body's immune system against cancer cells. Its therapeutic approaches aim to overcome resistance to conventional chemotherapies and offer new hope for patients with various types of cancer. The company conducts clinical trials and collaborates with prominent partners in oncology research to bring innovative treatment options to the market. Panbela Therapeutics, Inc. (PBLA) shares may be an attractive investment opportunity for investors interested in the pharmaceutical and biotechnology sectors and seeking an investment in a company dedicated to fighting cancer with innovative treatment methods.

Sector

Healthcare

Industry

Biotechnology

CEO

Jennifer K. Simpson

Employees

8

Headquarters

Waconia

Upcoming events

13 NOV

Earnings

Upcoming earnings report

52d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.